62nd Directing Council 77th Session of the Regional Committee of WHO for the Americas on the Prevention and Control of Noncommunicable Diseases
On 30 September 2025 in Washington, D.C., IFPMA and FIFARMA delivered a statement on Agenda Item 4.5 Plan of Action on Noncommunicable Disease Prevention and Control 2025–2030 during the 77th Session of the Regional Committee of WHO for the Americas.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the Latin American Federation of the Pharmaceutical Industry (FIFARMA) welcome WHO and PAHO’s continued efforts to tackle the rise of non-communicable diseases.
The High-Level Meeting on NCDs and Mental Health, which took place last week, has had an important role in rallying global efforts to ensure there is the right political commitment to tackle the growing global burden of NCDs across the globe.
There is an opportunity to capture the momentum of the UN High-Level Meeting to bend the curve against NCDs in the Americas and the world.
The draft Declaration includes welcome recognition of the critical role of research and innovation, the importance of vaccines and immunization as part of NCD prevention, and the need for integrated approaches to these diseases, considering the interconnectedness of chronic conditions. A life-course approach to preventing and tackling NCDs is the only way to reduce the huge burden placed on patients and healthcare systems worldwide.
Looking ahead, we have an opportunity for countries to go further to support healthier populations, resilient healthcare systems, and stronger economies. New research published by IFPMA earlier this year, demonstrated that by investing an additional 1% of GDP in public healthcare spending, where at least 40% of this is aimed at preventing and treating NCDs, close to 5 million lives could be saved each year in low- and middle-income countries.
Our industry remains a committed stakeholder in tackling NCDs. With more than 1,400 NCDs medicines launched in the past 10 years, and 75% of our R&D pipeline dedicated to NCDs and their risk factors, we are optimistic about the benefits that scientific innovation will bring to millions of patients. We will continue working with others to build solutions and contribute towards stronger health systems to improve the lives of people living with NCDs.
a joint statement BY:
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
